CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercial subsidiary, launched the Move Fibro Forward campaign to bring awareness and support to individuals impacted by fibromyalgia, a debilitating condition with no new FDA-approved treatments in over 15 years.

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

Accelerating order quantities from Tier-1 customer, with further mass production orders expected from potential Programs of Record with the U.S. Department of Defense (DoD)

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2025 Second Quarter Conference Call/Webcast Scheduled for Tuesday, August 5, 2025.

EVERETT, Wash.--(BUSINESS WIRE)--Funko, Inc. (Nasdaq: FNKO), a leading pop culture lifestyle brand, today announced that it will host a conference call on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025. The conference call will be webcast and can be accessed on the investor relations section of the Funko website at https://investor.funko.com. After the call, a replay of the webcast will be available on the same website. Abou.

The wireless carrier hiked its outlook for earnings per share and free cash flow on Monday.

ADDISON, Texas--(BUSINESS WIRE)-- #gnty--Guaranty Bancshares, Inc. (NYSE: GNTY) (the "Company," "we," "us," or "our"), the parent company of Guaranty Bank & Trust, N.A. (the "Bank"), today reported financial results for the fiscal quarter ended June 30, 2025. The Company's net income available to common shareholders was $10.0 million, or $0.88 per basic share, for the quarter ended June 30, 2025, compared to $8.6 million, or $0.76 per basic share, for the quarter ended March 31, 2025 and $7.4 milli.

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026

Agrees to issue approximately $10 Million Convertible Notes at $13 per share, a 198% premium to July 18 close $189 million raised year-to-date through hallmark DeFi/TradFi Accretion Flywheel strategy SILVER SPRING, MD, July 21, 2025 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced that the combined market value of its 55,788 ETH holdings, cash1, and other liquid holdings are approximately $242.2 million, based on an ETH price of $3,600. Additionally, the Company has agreed to issue $10 million in convertible notes through its previously established …

NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation.

Nokia CorporationStock Exchange Release21 July 2025 at 14:00 EEST Changes in Nokia Corporation's own shares Espoo, Finland – A total of 11 148 Nokia shares (NOKIA) held by the company were transferred today without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plans as announced on 22 November 2024. The number of own shares held by Nokia Corporation following the transfer is 64 685 389.

TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) announced (i) the release of the results of its previously announced eight separate offers (the “Offers”) to purchase for cash any and all of the outstanding notes of each series listed in the table below (collectively, the “Notes”), and (ii) that Rogers is increasing the aggregate Total Consideration payable for all Notes it will accept for purchase in the Offers, excluding accrued but unpaid interest, from the previously announced amount of US$1,250,000,000 to US$1,400,000,000 (the “Consideration Cap Amount”). The increased …

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026 Additional Phase 1 cohort designed to evaluate potential early proof of concept in subjects with increased cardiovascular disease (CVD) risk and elevated CRP BOSTON, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first subjects have been dosed in a Phase 1 study evaluating MRT-8102, …

DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced the separation of the roles of Chairman of the Board of Directors (“Board”) and Chief Executive Officer with the appointment of Thomas O. Hicks as Chairman of the Board and James G.

Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia

RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--BMS's Supplemental New Drug Application for Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review.

Verizon raised the lower end of its annual profit forecast on Monday, as strong demand for its higher-tier plans powered better-than-expected earnings in the second quarter.

Fresh Del Monte's strategic investments in logistics and product mix have driven margin expansion and operational stability despite flat revenue and macro uncertainty. The company's robust global supply chain and focus on high-demand, less perishable fruits like bananas, pineapples, and avocados underpin its resilience and growth. Valuation remains attractive with a consistent price-to-operating income ratio, making the stock undervalued given forward earnings expectations and market trends.

The wireless carrier faces stiff competition from rivals' promotions.